Novartis announced $5 billion buybackStaff Writer | January 25, 2017
Novartis announced a $5 billion share buyback as it said earnings dipped in the fourth quarter of the year, largely due to the effect of the strong dollar.
Pharma industry The effect of the strong dollar
Adjusting for the strength of the dollar, revenue and net income were flat, as falling sales from old cancer medicine Gleevec offset growth of some of Novartis's newer drugs. ■